Skip to main content

Table 8 Univariate analysis for predictors of OS since CNS metastases

From: Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer

Variables

No. of patients (%)

OS since CNS metastases, mo (95% CI)

P value

Age (yrs)

  

0.150

  <60

16 (55.2)

15.3 (3.7-26.9)

 

  > = 60

13 (44.8)

9.4 (4.9-13.9)

 

FIGO stage

  

0.069

  1,2

3 (10.3)

32.3 (16.9-47.7)

 

  3,4

26 (89.7)

11.7 (9.5-13.9)

 

Pathology of primary cancer

 

0.824

  Serous

16 (55.2)

11.7 (9.9-13.5)

 

  Non-serous

13 (44.8)

15.3 (6.1-24.5)

 

Histological grade

  

0.391

  1,2

5 (21.7)

22.7 (3.7-41.7)

 

  3,

18 (78.3)

11.7 (9.6-13.8)

 

Extent of surgical resection

 

0.211*

  TAH + BSO

23 (79.3)

13.2 (7.6-18.8)

 

  Limited

5 (17.2)

16.2 (4.5-19.3)

 

  Biopsy

1 (3.4)

1.0

 

Lymph node metastasis

 

0.372

  No

11 (37.9)

20.4 (8.4-32.4)

 

  Yes

18 (62.1)

11.7 (9.4-14.0)

 

Ascites at the time of primary surgery

0.421

  No

10 (34.5)

15.3 (1.7-28.9)

 

  Yes

19 (65.5)

12.5 (9.9-15.1)

 

Adjuvant therapy

  

0.071†

  Chemotherapy

25 (86.2)

15.3 (8.0-22.6)

 

  Chemotherapy + Radiotherapy

3 (10.3)

7.0 (1.5-12.4)

 

  None

1 (3.4)

32.3

 

Platinum sensitivity

  

0.033

  Sensitive

16 (57.1)

15.3 (0.5-30.1)

 

  Resistant

12 (42.9)

9.4 (0.1-18.9)

 

CD133 expression in primary cancer

 

0.001

  Negative

15 (51.7)

25.5 (10.4-40.6)

 

  VPositive

14 (48.3)

9.4 (2.4-16.4)

 

KPS score

  

0.412

  > = 80

14 (48.3)

13.2 (1.0-29.2)

 

  <80

15 (51.7)

12.5 (1.1-23.9)

 

No. of metastases

  

0.027

  Single

11 (37.9)

25.5 (12.6-38.4)

 

  Multiple

18 (62.1)

9.4 (4.4-14.4)

 

Prior cancer relapse before the diagnosis of CNS metastasis

0.053

  No

24 (82.8)

15.3 (6.4-24.2)

 

  Yes

5 (17.2)

9.4 (3.3-21.2)

 

Presence of extracranial disease

 

0.458

  No

16 (55.2)

13.2 (3.1-23.3)

 

  Yes

13 (44.8)

12.5 (5.4-19.6)

 

Treatment of CNS metastases

 

0.027‡

  Steroids

2 (6.9)

1.0 (0–5.292)

 

  Unimodal (WBRT or Neurosurgery)

9 (31.0)

8.0 (3.0-13.0)

 

  Multimodal including WBRT (Neurosurgery + WBRT +/− chemotherapy)

10 (34.5)

13.2 (7.5-18.9)

 

  Multimodal including SRS (SRS +/− neurosurgery +/− chemotherapy)

8 (27.6)

27.3 (15.1-39.5)

 

CD133 expression in CNS metastases

 

0.005§

  Negative

3 (15.8)

42.1 (31.4-46.2)

 

  Positive single cell

4 (21.1)

27.3 (25.1-29.6)

 

  Positive cluster

12 (63.2)

11.6 (8.5-14.7)

 

Time to CNS metastases (mo)

 

0.122

  <23.5

14 (48.3)

7.6 (0.78-20.25)

 

  > = 23.5

15 (51.7)

15.3 (1.41-29.19)

 
  1. Abbreviations: TAH Total abdominal hysterectomy, BSO Bilateral salpingo-oophorectomy, KPS Karnofsky performance status, WBRT Whole-brain radiation therapy, SRS Stereotactic radiosurgery.
  2. *P = 0.211 for TAH + BSO vs. Limited, P <0.0001 for TAH + BSO vs. Biopsy, P = 0.025 for Limited vs. Biopsy.
  3. †P = 0.071 for Chemotherapy vs. Chemotherapy + Radiotherapy, P = 0.412 for Chemotherapy vs. None, P = 0.182 for Chemotherapy + Radiotherapy vs. None.
  4. ‡P = 0.027 for Steroids vs. Unimodal, P <0.0001 for Steroids vs. Multimodal including WBRT, P = 0.001 for Steroids vs. Multimodal including SRS, P = 0.022 for Unimodal vs. Multimodal including WBRT, P <0.0001 for Unimodal vs. Multimodal including SRS, P = 0.020 for Multimodal including WBRT vs. Multimodal including SRS.
  5. §P = 0.005 for negative vs. positive cluster , P = 0.023 for positive single cell vs. positive cluster, P = 0.075 for negative vs. positive single cell.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us